plp (139 151)

PLP (139-151) is the amino acid fragment from positions 139 to 151 of myelin proteolipid protein (PLP), and can be used to induce the relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) model.

Plp(139-151) trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64674.

[L144-PLP(139-151)], a peptide ligand of the T cell receptor (TCR), acts as a TCR antagonist specifically inhibiting the activation of encephalitogenic Th1 clones [1].

[Gln144]-PLP(139-151) is an experimental antigen employed to investigate the cross-reactivity of T cells to self and non-self antigens. It activates T cells by binding to the T-cell Receptor (TCR), initiating an immune response. It is useful in the study of autoimmune disease regulation.

[Leu144,Arg147]-PLP (139-151) is a modified peptide fragment derived from myelin proteolipid protein (PLP), where leucine and arginine have replaced tryptophan and histidine at positions 144 and 147, respectively. This mutant also functions as a T cell receptor (TCR) antagonist, inhibiting the activation of encephalitogenic Th1 clones in vitro. Additionally, [Leu144,Arg147]-PLP (139-151) can impede the progression of experimental autoimmune encephalomyelitis (EAE).

[Leu144,Arg147]-PLP (139-151) is a mutated fragment of the myelin proteolipid protein (PLP), featuring substitutions of tryptophan to leucine and histidine to arginine at positions 144 and 147, respectively. Immunizing mice with this peptide (50 µg) mixed in complete Freund's adjuvant (CFA) elevates IL-4 levels in the spleen. While it suppresses Th1 cell activation in vitro, it does not do so in vivo; instead, it promotes the development of regulatory T cells. Preimmunization with [Leu144, Arg147]-PLP (139-151) postpones the onset of experimental autoimmune encephalomyelitis (EAE) triggered by encephalitogenic peptides from PLP (178-191), myelin oligodendrocyte glycoprotein (MOG) (92-106), or myelin basic protein (MBP) in mice.

[SER140]-PLP(139-151) is a polypeptide fragment derived from the myelin-associated lipid protein.

[SER140]-PLP(139-151) acetate is a peptide fragment from myelin proteolipid protein (PLP).

[SER140]-PLP(139-151) (TFA) is a polypeptide fragment of the myelin lipid protein.

PLP (178-191), an immunodominant encephalitogenic epitope from the proteolipid protein (PLP) fragment spanning amino acids 178 to 191, plays a pivotal role in SJL mice. It initiates disease onset earlier compared to the other major encephalitogenic epitope, PLP (139-151), though both epitopes result in similar incidence, severity, and histologic characteristics.

J5 peptide, an MBP inhibitor, competitively inhibits the binding of MBP 85-99 to HLA-DR2, and mitigates PLP 139-151/MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. It is utilized in research pertaining to inflammatory and immune diseases [1].